| For: | Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143 [PMID: 36683717 DOI: 10.3748/wjg.v29.i1.126] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i1/126.htm |
| Number | Citing Articles |
| 1 |
Mengmeng Yang, Longqing Xia, Jia Song, Huiqing Hu, Nan Zang, Jingwen Yang, Ying Zou, Liming Wang, Xiaoyue Zheng, Qin He, Jidong Liu, Fuqiang Liu, Kai Liang, Lei Sun, Li Chen. Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation. Lipids in Health and Disease 2023; 22(1) doi: 10.1186/s12944-023-01969-y
|
| 2 |
Xiuxian Huang, Zhengming Li, Zhenwei Zhai, Qiu Wang, Rongyan Wei, Jiacheng Mo, Jianhao Huang, Wensheng Lu. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and MACCEs in Patients with Diabetic Foot Ulcers: An Ambispective Longitudinal Cohort Study. Diabetes, Metabolic Syndrome and Obesity 2024; doi: 10.2147/DMSO.S447897
|
| 3 |
Salvatore Greco, Michele Campigotto, Andrea D’Amuri, Nicolò Fabbri, Angelina Passaro. Dyslipidemia, Cholangitis and Fatty Liver Disease: The Close Underexplored Relationship: A Narrative Review. Journal of Clinical Medicine 2024; 13(9) doi: 10.3390/jcm13092714
|
| 4 |
Vipul Wayal, Chang-Chi Hsieh. Bioactive dipeptides mitigate high-fat and high-fructose corn syrup diet-induced metabolic-associated fatty liver disease via upregulation of Nrf2/HO-1 expressions in C57BL/6J mice. Biomedicine & Pharmacotherapy 2023; 168 doi: 10.1016/j.biopha.2023.115724
|
| 5 |
Hai Nguyen Ngoc Dang, Tien Anh Hoang, Binh Anh Ho, Thang Chi Doan, Hung Minh Nguyen, Huyen Trang Tran Thi, Tien Thi Le, The Trung Le, Hung Minh Vu, Bich Ngoc Hoang Thi, Hoa Tran, Thang Viet Luong. Integrating liver and heart health: Cardiovascular risk reduction in patients with metabolic-associated steatotic liver disease. World Journal of Cardiology 2025; 17(7): 107751 doi: 10.4330/wjc.v17.i7.107751
|
| 6 |
Francis Msagati, Baraka Alphonce, Emmanuel Sindato. Prevalence, demographic characteristics and clinical profile of metabolic dysfunction-associated fatty liver disease among adult patients attending tertiary hospitals in Dodoma, Tanzania. a cross-sectional study. BMC Gastroenterology 2025; 25(1) doi: 10.1186/s12876-025-04233-y
|
| 7 |
Chao Cen, Zhongwen Fan, Xinjiang Ding, Xinyue Tu, Yuanxing Liu. Associations between metabolic dysfunction-associated fatty liver disease, chronic kidney disease, and abdominal obesity: a national retrospective cohort study. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-63386-0
|
| 8 |
Marwa Matboli, Manar Fouad Ahmed, Amany Helmy Hasanin, Reham Hussein Mohamed, Eman H. Eltantawy, Ghada Galal Hamam, Marwa Ramadan M. Abdelhalim, Maryam Elmasry, Marwa M. El-Shafei, Shaimaa Hamady. Amlodipine and perindopril modulate miR-874-3p expression to regulate ferroptosis-linked LPCAT3/LACS4/GPX4 Axis and gut dysbiosis in metabolic-associated steatohepatitis. International Immunopharmacology 2025; 164 doi: 10.1016/j.intimp.2025.115333
|
| 9 |
Fahad Lakhdhir, Agha Syed Muhammad, Ahmed Nasir Qureshi, Imran A Shaikh, Imran Joher, Jawaria Majeed, Javaria Khan . Assessing Mortality Disparities Among Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction Fatty Liver Disease and Metabolic Dysfunction-Associated Liver Disease: A Comprehensive Meta-Analysis. Cureus 2024; doi: 10.7759/cureus.71639
|
| 10 |
Lianbao Zheng, Yuanhang Yang, Qun Ye, Fang Wang, Xiaohong Zhang, Zhengyu Hou, Chenghui Lu, Baoming Tian, Renjie Liu, Tong Hu, Weihong Zhong. Cold-brewed yellow tea showed stronger inhibition on high-fat diet induced mice obesity than that hot brewed, due to higher non-ester catechins content based on metabolomic profile. 3 Biotech 2025; 15(10) doi: 10.1007/s13205-025-04492-2
|
| 11 |
Hamza Elbouny, Ayoub Amssayef, Rania Benjamaa, Mohammed Ajebli, Brahim Ouahzizi, Mohamed Bammou, Khalid Sellam, Chakib Alem. Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease. Nutrire 2025; 50(1) doi: 10.1186/s41110-024-00307-1
|
| 12 |
Felicia Darii, Silvia Stratulat, Angela Peltec, Zinaida Alexa, Olga Tagadiuc. Rolul scorurilor non-invazive în diagnosticul fibrozei hepatice la persoanele cu diabet zaharat tip 2. Public Health Economy and Management in Medicine 2026; (5(102)) doi: 10.52556/2587-3873.2024.5(102).11
|
| 13 |
Eleni Michalopoulou, John Thymis, Stamatios Lampsas, George Pavlidis, Konstantinos Katogiannis, Dimitrios Vlachomitros, Eleni Katsanaki, Gavriella Kostelli, Sotirios Pililis, Loukia Pliouta, Aikaterini Kountouri, Ioannis S. Papanikolaou, Vaia Lambadiari, Ignatios Ikonomidis. The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. Journal of Clinical Medicine 2025; 14(2) doi: 10.3390/jcm14020428
|
| 14 |
Fang Yao, Gaochao Wang, Fan Ning, Yanbo Shi. Targeting Ferroptosis: New Insights and Therapeutic Advances in MAFLD Complicating T2DM. Frontiers in Bioscience-Landmark 2025; 30(10) doi: 10.31083/FBL39735
|
| 15 |
Maria Fareed Siddiqui, Mehreen Rasheed, Imran Shahid, Imrana Tanvir, Sidra Khalid. Effect of Atenolol on Hepatic Dysfunction by Evaluating Level of AST. Pakistan BioMedical Journal 2023; doi: 10.54393/pbmj.v6i06.885
|
| 16 |
Ajayi Ayodeji Folorunsho, Oyowvi Mega Obukohwo, Akano Oyedayo Phillips, Olabisi Lateef Okeleji, Bernard Opeyemi Adedeji, Ajayi Lydia Oluwatoyin. Unveiling the Physiological Systemic Consequences of Adolescent Opioid Use: A Systematic Review. Journal of Child & Adolescent Substance Use 2025; 30(5) doi: 10.1080/29973368.2025.2546438
|
| 17 |
Darya Ivashkevich, Arina Ponomarenko, Igor Manzhulo, Inessa Dyuizen. Mechanistic Insights into N-Oleoylethanolamide-Mediated Hepatoprotection via PPAR-<b>α</b>. BIOCELL 2025; 49(4) doi: 10.32604/biocell.2025.061606
|
| 18 |
Cornelius J Fernandez, Lakshmi Nagendra, Joseph M Pappachan. Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action. touchREVIEWS in Endocrinology 2023; 20(1) doi: 10.17925/EE.2023.20.1.1
|
| 19 |
Maria Fareed Siddiqui, Mehreen Rasheed, Ahmad Alwazzan, Sadia Sarwar. Effect of Anti-Hypertensive Drug Atenolol on Liver Function by Evaluating ALT levels. Futuristic Biotechnology 2023; doi: 10.54393/fbt.v3i01.36
|
| 20 |
Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender. Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials. Journal of Basic and Clinical Physiology and Pharmacology 2025; 36(1) doi: 10.1515/jbcpp-2024-0140
|
| 21 |
Ana Lago-Sampedro, Wasima Oualla-Bachiri, Sara García-Serrano, Cristina Maldonado-Araque, Sergio Valdés, Viyey Doulatram-Gamgaram, Gabriel Olveira, Elias Delgado, Felipe Chaves, Luis Castaño, Alfonso Calle-Pascual, Josep Franch-Nadal, Gemma Rojo-Martínez, Eva García-Escobar. Protective Effect of High Adherence to Mediterranean Diet on the Risk of Incident Type-2 Diabetes in Subjects with MAFLD: The Di@bet.es Study. Nutrients 2024; 16(21) doi: 10.3390/nu16213788
|
| 22 |
Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia. Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment. Diabetes, Metabolic Syndrome and Obesity 2023; doi: 10.2147/DMSO.S431251
|
| 23 |
Said A. Al-Busafi, Mohammed Eslam. Liver Transplantation in the Era of Metabolic Dysfunction–Associated Fatty Liver Disease: Challenges, Ethical Dilemmas, and Future Directions. Transplantology 2025; 6(4) doi: 10.3390/transplantology6040035
|
| 24 |
Antelm Pujol, Pilar Sanchis, María I. Tamayo, Samantha Godoy, Paula Calvó, Asier Olmos, Pilar Andrés, Aleksandra Speranskaya, Ana Espino, Ana Estremera, Elena Rigo, Guillermo J. Amengual, Manuel Rodríguez, José Luis Ribes, Isabel Gomila, Félix Grases, Marta González-Freire, Lluís Masmiquel. Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study. Biomedicines 2024; 12(9) doi: 10.3390/biomedicines12091993
|
| 25 |
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies. Letters in Applied NanoBioScience 2026; 15(1) doi: 10.33263/LIANBS151.011
|
| 26 |
Zichen Zhang, Nuo Chen, Xiaojing Yuan, Jie Li, Wan Zhou. Glycogen metabolic dysfunction in T2DM with MASLD: linking α-hydroxybutyrate to GYS2 downregulation. Frontiers in Nutrition 2026; 13 doi: 10.3389/fnut.2026.1860017
|
| 27 |
Nitin Kapoor, Sanjay Kalra. Metabolic-Associated Fatty Liver Disease and Diabetes. Endocrinology and Metabolism Clinics of North America 2023; 52(3) doi: 10.1016/j.ecl.2023.02.006
|
| 28 |
Othman A. Alghamdi. Pancreatic Lipase Inhibitors as Therapeutic Agents for Metabolic Disorders: Advances in Molecular Biology and Biotechnology: A Review. Industrial Biotechnology 2026; 22(1) doi: 10.1177/15509087251389397
|
| 29 |
Kirthika Venkatesan, Nisha Nigil Haroon. Management of Metabolic-Associated Fatty Liver Disease. Endocrinology and Metabolism Clinics of North America 2023; 52(3) doi: 10.1016/j.ecl.2023.02.002
|
| 30 |
Xingyu Zhang, Jie Li, Mei Yang, Hong Huang, Hao Wang, Hongmin Zhang. Accurate and sensitive low-density lipoprotein (LDL) detection based on the proximity ligation assisted rolling circle amplification (RCA). Analytical Methods 2024; 16(13) doi: 10.1039/D4AY00070F
|
| 31 |
Mauro Garcia-Altieri, Keila Carrera-Mejias, Ruben Hernaez. Management of depression/anxiety in patients with chronic liver disease. Clinical Liver Disease 2024; 23(1) doi: 10.1097/CLD.0000000000000179
|
| 32 |
Andreas I Biris, Ioannis Karamatzanis, Despoina Biri, Ioannis A Biris , Nikolaos Maravegias. Non-Invasive Ultrasound Diagnostic Techniques for Steatotic Liver Disease and Focal Liver Lesions: 2D, Colour Doppler, 3D, Two-Dimensional Shear Wave Elastography (2D-SWE), and Ultrasound-Guided Attenuation Parameter (UGAP). Cureus 2024; doi: 10.7759/cureus.72087
|
| 33 |
Huanjia Qu, Lingling Zhou, Dong Tang, Qiuling Zhang, Pu Yang, Boyi Yang, Junping Shi. Relationship between liver fat, pancreatic fat, and new-onset type 2 diabetes mellitus in patients with metabolic dysfunction-associated fatty liver disease. Acta Diabetologica 2025; 62(10) doi: 10.1007/s00592-025-02501-7
|
| 34 |
Suxia Li, Yaxi Zhang, Peipei Li, Xuan Xue, Lijuan Huo. IL-22 attenuates MAFLD progression by modulating oxidative stress and ferroptosis. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-28718-8
|
| 35 |
E. V. Biryukova. Non-alcoholic fatty liver disease: a current challenge of interdisciplinary research. Meditsinskiy sovet = Medical Council 2024; (6) doi: 10.21518/ms2024-159
|
| 36 |
O.M. Radchenko, O.J. Komarytsia, M.O. Borovets, R.S. Ivasivka, R.R. Guta. Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) 2024; 20(3) doi: 10.22141/2224-0721.20.3.2024.1389
|
| 37 |
Kim Henriksen, M. V. Chakravarthy, C. L. Bager, A. T. Larsen, K. E. Mohamed, M. A. Karsdal. The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss. Diabetes, Obesity and Metabolism 2025; 27(7) doi: 10.1111/dom.16379
|
| 38 |
Beyond Glucose: Empagliflozin’s Impact on Fatty Liver in Patients with Type 2 Diabetes; A True Game Changer. Indus Journal of Bioscience Research 2025; 3(2) doi: 10.70749/ijbr.v3i2.663
|
| 39 |
Marcio José Concepción-Zavaleta, José Paz-Ibarra, Alejandro Román-González, Luis Alberto Concepción-Urteaga, María Alejandra Quispe-Flores, Jhean Gabriel Gonzáles-Yovera, Luciana del Pilar Rafael-Robles, María del Carmen Durand-Vásquez, Elman Rolando Gamarra-Osorio, Juan Eduardo Quiroz-Aldave. From liver to hormones: The endocrine consequences of cirrhosis. World Journal of Gastroenterology 2024; 30(9): 1073-1095 doi: 10.3748/wjg.v30.i9.1073
|
| 40 |
Isaac Aguirre-Maldonado, Ema Elvira Herrera-López, Fernando López-Zenteno, Julio César Ramírez-Nava, Norma Arely López-Hernández, Jaime Arellanes-Robledo, Luis del Pozo-Yauner, Rebeca García-Román, Hilda Montero, Alfonso Alexander-Aguilera, Juana Martha Noyola-Díaz, Javier Camacho, Julio Isael Pérez-Carreón. Intriguing hepatoprotective effects of sucrose on hepatocellular carcinoma pathogenesis. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-74991-4
|
| 41 |
Vignesh Rajan, Ambarish Das, J. Venkatachalam, K. K. Lohani, Chandrakant Lahariya. Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review. Preventive Medicine: Research & Reviews 2025; 2(4) doi: 10.4103/PMRR.PMRR_159_24
|
| 42 |
Essam M Abdel Aziz, Rabea A Gadelkareem, Wael A Abbas, Marwa A Shehata, Nashwa M Azoz. Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?. World Journal of Nephrology 2026; 15(2): 118877 doi: 10.5527/wjn.v15.i2.118877
|
| 43 |
Ying Wu, Jiaqiang Zhou. Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice. Current Issues in Molecular Biology 2025; 47(3) doi: 10.3390/cimb47030148
|
| 44 |
N. S. Branovitskaya. Polymorphism of PNPLA3 and TM6SF2 genes in patients with nonalcoholic fatty liver disease resident at Gomel region. Health and Ecology Issues 2024; 21(3) doi: 10.51523/2708-6011.2024-21-3-06
|
| 45 |
Mohamed El-Kassas, Imam Waked, Mona Amin, Walaa Abdelhamed. Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges. World Journal of Gastroenterology 2025; 31(45): 111643 doi: 10.3748/wjg.v31.i45.111643
|
| 46 |
I. S. Sabirov, O. O. Karshina, A. I. Sabirova, A. N. Khalmatov. Metabolic-associated fatty liver disease and older age. Experimental and Clinical Gastroenterology 2024; (3) doi: 10.31146/1682-8658-ecg-223-3-25-32
|
| 47 |
Ming-Lun Yeh, Jee-Fu Huang, Chia-Yen Dai, Chung-Feng Huang, Ming-Lung Yu, Wan-Long Chuang. Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist. Expert Review of Gastroenterology & Hepatology 2024; 18(8) doi: 10.1080/17474124.2024.2388790
|
| 48 |
|
| 49 |
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic. MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development. Current Issues in Molecular Biology 2024; 46(7) doi: 10.3390/cimb46070376
|